Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2022;10(12):6 Psychopharmacology (Berl). 2021 11-Apr;():. 10.1007/s00213-020-05692-9What this means for my practice?
A single dose of ayahuasca appears to reduce suicidality in patients with major depressive disorder. Controlled studies with larger sample sizes are needed.
Study Summary
A secondary analysis of a case series of 17 patients with major depressive disorder examined the effects of a single dose of ayahuasca on suicidality. Suicidality was assessed using the suicidality subscale of the Montgomery-Asberg Depression Rating Scale (MADRS-SI). The study found a decrease in suicidality beginning 40 minutes after ingestion of ayahuasca, which continued decreasing to 21 days after ingestion of the single dose. The improvements were significant at all timepoints.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
Are you affiliated with one of our partner associations?
Click here to gain complimentary access as part your association member benefits!